Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its pre...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
VistaGen Therapeutics ( VTGN ) receives $5M non-dilutive upfront license payment from EverInsight Therapeutics, the Company's partner for development and commercialization of PH94B for anxiety-related disorders in Asia. More news on: VistaGen Therapeutics, Inc., Healthcare stocks ne...
SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Aug. 4, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced r...
VistaGen Therapeutics ( OTC:VTGN ) has priced its public offering of 15,625,000 common shares at $0.80/share, for expected gross proceeds of $12.5M. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its und...
VistaGen Therapeutics (NASDAQ: VTGN ) -14% AH commenced an underwritten public offering of shares. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Based on FDA feedback, VistaGen (NASDAQ: VTGN ) has clarified key aspects of its planned Phase 3 clinical trial evaluating lead drug PH94B, a rapid-onset neurosteroid nasal spray, for the acute treatment of anxiety in adults with social anxiety disorder (SAD), a Fast Track-tagged indicat...
SOUTH SAN FRANCISCO, Calif. , July 23, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, announced the results of a positive meeti...
VistaGen Therapeutics (NASDAQ: VTGN ): FY GAAP EPS of -$0.50. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...